| Cancer Research |
 |
Clinical Trials |
For more information regarding these studies, please contact Tracy Ackley at #795-7549 or 795-2935.
BREAST
CALGB 40101
Cyclophosphamide and Doxorubicin (CA) (4 vs. 6 cycles) versus Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Women with Node-Negative Breast Cancer: A 2x2 Factorial Phase III Randomized Study.
SWOG S0226
Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer
MA.27
A Randomized Phase III Trial of Exemestane versus Anastrozole in Postmenopausal Women with Receptor Positive Primary Breast Cancer
MA.27B
The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density in Postmenopausal Women with Primary Breast Cancer (Mandatory companion study to MA.27)
MA.27D
The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence (Mandatory companion study to MA.27)
IBCSG 25-02
A Phase III Trial of Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
NSABP B-39/RTOG 0413
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
NSABP B-42
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
BLADDER
CANCER CONTROL
GASTROINTESTINAL
CALGB 80101
Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma
CALGB 80405
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
CST1571BUS227
Gastrointestinal Stromal Tumors (GIST) Registry Protocol (Observational Database)
LEUKEMIA
CALGB 9665
The CALGB Leukemia Tissue Bank--(Laboratory Companion Study)
CALGB 8461
Cytogenetic Studies in Acute Leukemia--(Laboratory Companion Study)
CALGB 10105
A Phase II Study of an Oral VEGF Receptor Tyrosine Kinase Inhibitor (PTK787/ZK 222584) (IND# 66370, NSC# 719335) in Myelodysplastic Syndrome (MDS)
LYMPHOMA
MELANOMA
ECOG 2603
A Double-blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma
PROSTATE
CALGB 9594
Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III
CALGB 90202
A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone
CALGB 90401
A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab (IND# 7921, NSC# 704865) in Men with Hormone Refractory Prostate Cancer
RESPIRATORY
RTOG 0214
A Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients with Locally Advanced Non-Small Cell Lung Cancer
SWOG 0424
Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men
RTOG 0123
A Phase II Randomized Trial with Captopril in Patients Who have Received radiation therapy +/- Chemotherapy for Stage II-IIIB Non-Small Cell Lung Cancer, Stage I Central Non-Small Cell Lung Cancer, or Limited-Stage Small-Cell Lung Cancer
SYMPTOM CONTROL
C2006-01
A PivotalPhase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi for the Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following the Administration of Either Moderately or Highly Emetogenic Chemotherapy Regimens
CMMC Oncology Protocols - June 2007
|
